Shanthi Rexaline

Shanthi is a contributor to InvestorPlace.com and works as a Staff Writer with Benzinga. Equipped with a Bachelor’s degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors.

Recent Articles

Palantir Investors Should Shift Into Neutral Until Growth Picks Up

By Shanthi Rexaline

PLTR stock has now lost about three-fourth of its peak valuation. Both external and internal factors have played a role in its sell-off.

7 U.S.-listed China Stocks Trading At Extremely Cheap Valuations

By Shanthi Rexaline

Some high-quality China stocks are selling at bargains. The space is definitely worth taking a look at for those willing to ride the risk.

TSM Stock Is a Play on Semiconductor Industry’s Secular Growth Trends

By Shanthi Rexaline

TSMC's chips power a slew of applications and devices and its technological leadership positions TSM stock on the superhighway of growth.

7 Biotech Stocks With Key Catalysts in March

By Shanthi Rexaline

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.

Novavax Revenue Guidance Does Little to Change Neutral Stance on the Stock

By Shanthi Rexaline

NVAX stock continues to languish for want of evidence for a sustainable fundamental improvement. The 2022 revenue guidance issued by the company did stir some optimism, but investors have quickly fallen back to their guarded stance.

Load More